Organogenesis Holdings Inc. (ORGO)
- Previous Close
2.8600 - Open
2.8200 - Bid 2.8900 x 200
- Ask 2.9200 x 200
- Day's Range
2.8100 - 2.9100 - 52 Week Range
1.7950 - 4.7050 - Volume
421,209 - Avg. Volume
737,882 - Market Cap (intraday)
382.693M - Beta (5Y Monthly) 1.57
- PE Ratio (TTM)
72.50 - EPS (TTM)
0.0400 - Earnings Date May 8, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
4.83
Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage. Its products also include FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; PuraPly MZ, a micronized particulate version of PuraPly for the management of open wounds in the surgical setting; and CYGNUS Dual, a dehydrated placental tissue preserved to retain the ECM scaffold. The company's pipeline products include ReNu, a cryopreserved suspension used to support healing of soft tissues; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; and TransCyte, a bioengineered tissue for the treatment of partial thickness burns. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales representives and independent agencies. Organogenesis Holdings Inc. was founded in 1985 and is headquartered in Canton, Massachusetts.
organogenesis.com862
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: ORGO
Performance Overview: ORGO
Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ORGO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ORGO
Valuation Measures
Market Cap
384.01M
Enterprise Value
399.52M
Trailing P/E
72.75
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.89
Price/Book (mrq)
1.38
Enterprise Value/Revenue
0.92
Enterprise Value/EBITDA
11.09
Financial Highlights
Profitability and Income Statement
Profit Margin
1.14%
Return on Assets (ttm)
2.24%
Return on Equity (ttm)
1.82%
Revenue (ttm)
433.14M
Net Income Avi to Common (ttm)
4.95M
Diluted EPS (ttm)
0.0400
Balance Sheet and Cash Flow
Total Cash (mrq)
103.84M
Total Debt/Equity (mrq)
43.67%
Levered Free Cash Flow (ttm)
18M
Research Analysis: ORGO
Analyst Price Targets
Fair Value
Analyst Recommendations
Earnings
Research Reports: ORGO
Daily – Vickers Top Buyers & Sellers for 01/12/2024
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
ORGO: What does Argus have to say about ORGO?
ORGANOGENESIS HOLDINGS INC has an Investment Rating of SELL; a target price of $2.000000; an Industry Subrating of Medium; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Medium; and a Value Subrating of Low.
RatingBearishPrice TargetORGO: What does Argus have to say about ORGO?
ORGANOGENESIS HOLDINGS INC has an Investment Rating of SELL; a target price of $2.000000; an Industry Subrating of Medium; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Low.
RatingBearishPrice TargetORGO: What does Argus have to say about ORGO?
ORGANOGENESIS HOLDINGS INC has an Investment Rating of SELL; a target price of $2.000000; an Industry Subrating of High; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Low.
RatingBearishPrice Target